Natalizumab and beyond

European Neurology

Volumn 64, Issue 4, 2010, Pages 236-240

  Yildiz, Murat ^a   Tettenborn, Barbara ^a   Putzki, Norman ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; METHYLPREDNISOLONE; NATALIZUMAB;

ADULT; ATAXIA; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LETTER; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RELAPSE; REMISSION; VERTIGO;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 77956252411     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000317583     Document Type: Letter

References (36)

1. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L , Miller DH, et al: A randomized, placebo-controlled trial of na-talizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
2. European Medicines Agency. Natalizumab Elan Pharma: natalizumab.http:// www.ema.europa.eu/ema/index.jsp?curl=pages/medi-cines/human/medicines/000624/ human- med-000919.jsp&mid=WC0b01ac058001d1 24&murl=menus/medicines/ medicines. jsp&jsenabled=true.
3. Putzki N, Yaldizli O, Bühler R, et al: Natali-zumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland. Eur J Neurol 2010; 63:101-106.
4. FDA: FDA Drug Safety Communication: Risk of Progressive Multifocal Leukoen-cephalopathy (PML) with the use of Tysabri (natalizumab). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInfor- mationforPatientsandProviders/ucm199872.htm (accessed February 8, 2010).
5. Confavreux C, Vukusic S: Non-specific immunosuppressants in the treatment of multiple sclerosis. Clin Neurol Neurosurg 2004; 10 6 : 263-269.
6. Rizvi SA, Agius MA: Current approved options for treating patients with multiple sclerosis. Neurology 2004; 63(suppl 6):S8-S14.
7. Dorsey ER, Thompson JP, Noyes K, et al: Quantifying the risks and benefits of natali-zumab in relapsing multiple sclerosis. Neurology 2007; 68:1524-1528.
8. Sorensen PS: How effective is natalizumab as second-line treatment for multiple sclerosis in daily clinical praxis? Eur J Neurol 2009; 16 : 287-288.
9. Oturai AB, Koch-Henriksen N, Petersen T, Jensen PE, Sellebjerg F, Sorensen PS: Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. Eur J Neurol 2009; 16:420-423.
10. Hutchinson M, Kappos L, Calabresi PA: The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol 2009; 256:405-415.
11. Putzki N, Kollia K, Woods S, et al: Natali-zumab is effective as second-line therapy in the treatment of relapsing remitting MS. Eur J Neurol 2009; 16:424-426.
12. Pachner AR, Warth JD, Pace A: Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study. Neu-rolog y 2009; 73: 1493-1500.
13. Hartung HP, Munschauer F, Schellekens H: Significance of neutralizing antibodies to in-terferon beta during treatment of multiple sclerosis: expert opinions based on the proceedings of an international consensus conference. Eur J Neurol 2005; 12: 588-601.
14. Caon C, Din M, Ching W, et al: Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis. Eur J Neurol 2006; 13: 471-474.
15. Limmroth V, Putzki N: High-dose , frequently administered interferon-beta. J Neurol Sci 2005; 15:95-96.
16. Carra A, Onaha P, Luetic B, et al: Therapeutic outcome 3 years after switching of im-munomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina. Eur J Neurol 2008; 15:386-393.
17. Gold R: Combination therapies in multiple sclerosis. J Neurol 2008; 255(suppl 1):51-60.
18. Vollmer T, Panitch H, Bar-Or A, et al: Gla-tiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler 2008; 14:663-670.
19. Hartung HP, Gonsette R, König N, et al: Mi-toxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360: 2018-2025.
20. Emmanuelle Le Page E,Leray E,Taurin G,et al.: Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5-year follow-up observational study of 100 consecutive patients, J Neurol Neurosurg Psychiatry, 2008, 79, 52-56
21. Goffette S, van Pesch V, Vanoverschelde JL, et al: Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone. J Neurol 2005; 252: 1217-1222.
22. Rivera V, AL-Sabbagh A, Bennett R, et al: RENEW study update XVIII: ongoing evaluation of the safety and tolerability of mito-xantrone in worsening multiple sclerosis. Mult Scler 2008; 14:S29.
23. Ghalie RG, Edan G, Laurent M, et al: Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurolog y 2002; 59: 909-913.
24. Cohen BA, Mikol DD: Mitoxantrone treatment of multiple sclerosis. Neurology 2004; 63(suppl 6):S28-S32.
25. Ghalie RG, Mauch E, Edan G, et al: A study of therapy-related acute leukaemia after mi-toxantrone therapy for multiple sclerosis. Mult Scler 2002; 8: 441-445.
26. Martinelli L: Late-breaking science program at the American Academy of Neurology's 61st Annual Meeting in Seattle, April 25 to May 2, 2009. http://www.aan.com/press/in-dex.cfm?fuseaction=release.view&release=725 (accessed February 8, 2010).
27. Ellis R, Boggild M: Therapy-related acute leukaemia with mitoxantrone: what is the risk and can we minimise it? Mult Scler 2009; 15:505-508.
28. Edan G, Brochet B, Clanet M, et al: Safety profile of mitoxantrone in a cohort of 802 multiple sclerosis patients: a 4-year mean follow-up study. Neurolog y 2004; 62(suppl 5):A493.
29. Weiner HL, Mackin GA, Orav EJ, et al: Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 1993; 43: 910-1008.
30. Weiner HL, Cohen JA: Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult Scler 2002; 8:142-154.
31. Cree BA, Lamb S, Morgan K, et al: An open label study of the effects of rituximab in neu-romyelitis optica. Neurology 2005; 64:1270-1272.
32. Meinl E, Krumbholz M, Hohlfeld R: B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation. Ann Neurol 2006; 59: 880-892.
33. Stüve O, Leussink VI, Fröhlich R, et al: Long-term B-lymphocyte depletion with ritux-imab in patients with relapsing-remitting multiple sclerosis. Arch Neurol 2009; 66: 259-261.
34. Kappos L, Bates D, Hartung HP, et al: Na-talizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 2007; 6:431-441.
35. Hellwig K, Schimrigk S, Fischer M, et al: Allergic and nonallergic infusion reactions during natalizumab therapy. Arch Neurol 2008; 65:656-658.
36. Sellebjerg F, Barnes D, Filippini G, et al: EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. Eur J Neurol 2005; 12:939-946.